Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147329
Status:
COMPLETED
Last Update Posted:
2007-02-23
First Post:
2005-09-06
Brief Title:
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Double-Blind Placebo-Controlled Randomized Study To Evaluate the Tolerability Pharmacokinetics Pharmacodynamics and Biologic Activity of MM-093 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Merrimack is conducting a research study to see if an experimental drug called MM-093 is safe and effective in the treatment of psoriasis MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein AFP Adults normally have very small amounts of AFP in their bloodstream However during pregnancy AFP levels in both the mother and the fetus are much higher than normal It has been observed that some women with psoriasis and other autoimmune diseases such as rheumatoid arthritis have fewer symptoms during pregnancy particularly during the third trimester At this time the levels of AFP in the blood of the mother and fetus are the highest This observation led Merrimack to begin examining MM-093 as a potential treatment for psoriasis This study is designed to further test the safety and effectiveness of MM-093 in patients with psoriasis
Detailed Description:
TBA
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None